References

Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019

10.1001/jamanetworkopen.2022.45269 · ExternalCitation · doi-reference

Long-Term Survival in Patients With Advanced Melanoma

10.1001/jamanetworkopen.2024.26641 · ExternalCitation · doi-reference

Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies

10.1001/jamaoncol.2017.5332 · ExternalCitation · doi-reference

Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients

10.1002/cncr.34716 · ExternalCitation · doi-reference

Re-examining the role of adjuvant radiation therapy

10.1002/jso.25329 · ExternalCitation · doi-reference

Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia

10.1007/s10637-024-01472-w · ExternalCitation · doi-reference

Radiation and Melanoma: Where Are We Now?

10.1007/s11912-024-01557-y · ExternalCitation · doi-reference

Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study

10.1016/j.annonc.2024.08.2330 · ExternalCitation · doi-reference

Arsenic trioxide-based nanoparticles for enhanced chemotherapy by activating pyroptosis

10.1016/j.apsb.2025.08.003 · ExternalCitation · doi-reference

Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma

10.1016/j.compbiomed.2024.108198 · ExternalCitation · doi-reference

Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis

10.1016/j.critrevonc.2020.103187 · ExternalCitation · doi-reference

Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis

10.1016/j.ejca.2021.09.019 · ExternalCitation · doi-reference

Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder

10.1016/j.jpba.2023.115937 · ExternalCitation · doi-reference

5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation

10.1016/j.xcrm.2025.102537 · ExternalCitation · doi-reference

NetAUC: A network-based multi-biomarker identification method by AUC optimization

10.1016/j.ymeth.2021.08.001 · ExternalCitation · doi-reference

Cutaneous melanoma

10.1016/s0140-6736(23)00821-8 · ExternalCitation · doi-reference

Radiotherapy, immunity, and immune checkpoint inhibitors

10.1016/s1470-2045(24)00075-5 · ExternalCitation · doi-reference

Inflammatory microenvironment remodelling by tumour cells after radiotherapy

10.1038/s41568-020-0246-1 · ExternalCitation · doi-reference

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

10.1056/nejmoa2109970 · ExternalCitation · doi-reference

Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

10.1056/nejmoa2407417 · ExternalCitation · doi-reference

Panoramic hybrid transmission topology and spatially adaptive sensitivity compensation EIT: Wide-field deep imaging via dual-array

10.1063/5.0320664 · ExternalCitation · doi-reference

Radiotherapy with or without immunotherapy in metastatic melanoma: Efficacy and tolerability

10.1080/0284186x.2023.2280766 · ExternalCitation · doi-reference

Radiotherapy-induced abscopal effects in immune checkpoint inhibitor-refractory metastatic disease: Results from a large multicenter real-world cohort study

10.1080/2162402x.2025.2610529 · ExternalCitation · doi-reference

Immunotherapy and radiotherapy in melanoma: A multidisciplinary comprehensive review

10.1080/21645515.2021.1903827 · ExternalCitation · doi-reference

CtDNA Dynamics Identifies Pseudoprogression in a Metastatic Melanoma Patient Treated With Nivolumab/Relatlimab

10.1097/cji.0000000000000569 · ExternalCitation · doi-reference

The role of circulating tumor DNA in the management of melanoma: A literature review

10.1097/cmr.0000000000001117 · ExternalCitation · doi-reference

FUNMarker: Fusion Network-Based Method to Identify Prognostic and Heterogeneous Breast Cancer Biomarkers

10.1109/tcbb.2020.2973148 · ExternalCitation · doi-reference

Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy

10.1111/j.1349-7006.2008.01021.x · ExternalCitation · doi-reference

CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes

10.1111/jvh.13886 · ExternalCitation · doi-reference

Abscopal effects in patients with malignant melanoma treated with radiotherapy and immune checkpoint inhibition: Analysis of a large observational multicenter study

10.1136/jitc-2025-012717 · ExternalCitation · doi-reference

Radiotherapy and immunotherapy in cancer treatment: Mechanisms of clinical synergy

10.1172/jci207550 · ExternalCitation · doi-reference

Sensitivity of Circulating Tumor DNA for Detection of Minimal Residual Disease Recurrence or Relapse in Patients with Melanoma

10.1200/oa-25-00119 · ExternalCitation · doi-reference

Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma

10.1200/po-25-00254 · ExternalCitation · doi-reference

Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients

10.18632/oncotarget.25053 · ExternalCitation · doi-reference

10.3389/fimmu.2024.1520441

10.3389/fimmu.2024.1520441 · ExternalCitation · doi-reference

10.3389/fimmu.2025.1689103

10.3389/fimmu.2025.1689103 · ExternalCitation · doi-reference

10.3390/cancers14174213

10.3390/cancers14174213 · ExternalCitation · doi-reference

10.3390/cancers16050854

10.3390/cancers16050854 · ExternalCitation · doi-reference